[ A23-117] Relugolix/estradiol/norethisterone acetate (endometriosis) – Benefit assessment according to §35a Social Code Book V
Last updated 01.03.2024
Project no.:
A23-117
Commission:
Commission awarded on 29.11.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Reproductive health and birth
Symptomatic treatment of adult women of reproductive age with endometriosis who have a history of previous medical or surgical treatment
- Women who are eligible for treatment with dienogest: added benefit not proven
- Women who are not (or no longer) eligible for treatment with dienogest: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A23-117_en
| Project no. | Title | Status |
|---|---|---|
| A21-112 | Relugolix/estradiol/norethisterone (uterine fibroid) - Benefit assessment according to §35a Social Code Book V | Commission completed |